Clinical trials: Inflammatory
Ulcerative Colitis (UC)
A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
This study was comprised of three substudies. The objective of Substudy 1 was to characterize the dose-response, efficacy, and safety of upadacitinib compared to placebo in inducing clinical remission to identify the induction…
- Trial name
- NCT02819635
- Testing
- Upadacitinib
- Where
- 496 sites in United States, Argentina and 44 more
- Volunteers
- 1,302 people
- Sponsor
- AbbVie
Breast Cancer
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
This 3 arm study will assess the tolerability, safety and efficacy of 3 neoadjuvant treatment regimens in participants with locally advanced, inflammatory or early stage human epidermal growth factor receptor 2 (HER2)-positive…
- Trial name
- NCT00976989
- Testing
- Pertuzumab, Trastuzumab, FEC
- Where
- 55 sites in Bosnia and Herzegovina, Brazil and 18 more
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
Allergic Conjunctivitis
A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy
A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft ® as Measured by In-Vivo Confocal Microscopy
- Trial name
- NCT02308501
- Testing
- Lastacaft ®
- Volunteers
- 25 people
- Sponsor
- ORA, Inc.
Ulcerative Colitis
Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis
This Phase II study is a randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of rhuMAb Beta7 in patients with moderate to severe ulcerative colitis.
- Trial name
- NCT01336465
- Testing
- rhuMAb Beta7
- Where
- 51 sites in United States, Australia and 9 more
- Volunteers
- 124 people
- Sponsor
- Genentech, Inc.
Osteoarthritis, Rheumatoid Arthritis
Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System
Prospective, multi-center clinical study to evaluate the clinical outcomes of the posterior stabilized design of the LCS® Complete Mobile-bearing Total Knee System
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis, Juvenile Arthritis
- Trial name
- NCT00487565
- Testing
- Total knee arthroplasty
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- DePuy Orthopaedics
Ulcerative Colitis
Propionyl-L-Carnitine in Ulcerative Colitis
The purpose of this study is to determine whether Propionyl-L-carnitine administration may ameliorate the illness in patients affected by mild to moderate ulcerative colitis already in treatment with one of the standard…
- Trial name
- NCT01026857
- Testing
- Propionyl-L-Carnitine
- Where
- 15 sites in Italy, Lithuania and 2 more
- Volunteers
- 121 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS)
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia
This is a Phase 3, randomized, blinded, and placebo-controlled clinical trial investigating a new combination treatment for critically ill adults who have severe community-acquired pneumonia, especially if they also have sepsis…
- Conditions
- Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis, Lymphopenia
- Trial name
- NCT07492875
- Testing
- Nogapendekin alfa inbakicept (NAI), agenT-797
- Sponsor
- ImmunityBio, Inc.
Coronary Heart Disease, Clonal Hematopoiesis of Indeterminate Potential (CHIP)
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
This Phase 2a clinical trial evaluated the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, or a single s.c.
- Trial name
- NCT06097663
- Testing
- MAS825, DFV890
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Sepsis, Septic Shock
Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study
The primary objective of this study is to establish an IL-6 concentration cutoff that predicts sepsis or septic shock (according to the Third International Consensus Definitions (Sepsis-3 criteria)) in patients who are admitted…
- Trial name
- SYMON III (NCT07425587)
- Where
- 5 sites in United States
- Volunteers
- 450 people
- Sponsor
- Bluejay Diagnostics, Inc.
Myositis
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
The purpose of this study is to evaluate the efficacy and safety of Nipocalimab versus placebo in participants with active idiopathic inflammatory myopathies (IIM).
- Trial name
- SPIREA (NCT05379634)
- Testing
- Nipocalimab, Glucocorticoids
- Where
- 57 sites in United States, Canada and 11 more
- Volunteers
- 36 people
- Sponsor
- Janssen Research & Development, LLC
Sepsis, Infection
Initial Feasibility Study of the CycloPE® Device
This is a single-center, prospective, single-arm clinical study to evaluate the feasibility, safety, and performance of the PATH EX CycloPE® device on suspected bacteremia-associated sepsis.
- Conditions
- Sepsis, Infection, Bacteremia Sepsis, Systemic Inflammatory Response Syndrome (SIRS)
- Trial name
- NCT06970899
- Testing
- PATH EX CycloPE® Device
- Where
- Armenia
- Volunteers
- 15 people
- Sponsor
- PATH EX, Inc.
Shock, Septic
Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock
This is a randomized, double-blind, placebo-controlled dose-selection study in which two doses of nangibotide are tested versus placebo.
- Trial name
- ASTONISH (NCT04055909)
- Testing
- nangibotide low dose, nangibotide high dose
- Where
- 43 sites in Belgium, Denmark and 4 more
- Volunteers
- 355 people
- Sponsor
- Inotrem
Healthy
A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS)
The purpose of this methodology study is to evaluate the effect of AZD8309 on cells and inflammatory biomarkers in nasal lavage and blood after nasal challenge with lipopolysaccharide (LPS)
- Trial name
- NCT00860821
- Testing
- AZD8309
- Where
- Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Crohn's Disease
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
The purpose of this study is to evaluate the long term efficacy, safety, and tolerability of repeated administration of adalimumab in participants with Crohn's disease.
- Trial name
- NCT02185014
- Testing
- Adalimumab
- Volunteers
- 252 people
- Sponsor
- AbbVie
Chronic Inflammatory Small Bowel Disease, Crohn's Disease
PillCam SBC System Functionality in Established and Suspected IBD Patients
This clinical study is designed to evaluate the PillCam SBC system performance in 50 established or suspected inflammatory bowel disease (IBD) patients by visualizing and assessing their small and large bowel.
- Trial name
- PIANO (NCT02742714)
- Testing
- PillCam SBC system
- Where
- 5 sites in Israel, Italy and 1 more
- Volunteers
- 54 people
- Sponsor
- Medtronic - MITG
Crohn's Disease
A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease
This study employs a multicenter, randomized, double-blind, placebo-controlled, parallel-group, continuous treatment design to evaluate the efficacy, safety, PPK characteristics, and PD effects of H021 Enteric-coated Tablets…
- Trial name
- NCT07677514
- Testing
- H021 Enteric-coated Tablets Low-dose Group, H021 Enteric-coated Tablets High-dose Group
- Where
- 24 sites in United States, China
- Volunteers
- 156 people
- Sponsor
- Jiangsu Carephar Pharmaceutical Co., Ltd.
Sepsis, Septic Shock
Multicenter Symphony IL-6 Monitoring Sepsis ICU Study
The primary objective of this study is to establish an IL-6 concentration cutoff and optimal time point(s) for using Symphony IL-6 that predict 28-day mortality in patients who are admitted or are intended to be admitted to the…
- Trial name
- SYMON (NCT06181604)
- Where
- 7 sites in United States
- Volunteers
- 143 people
- Sponsor
- Bluejay Diagnostics, Inc.
Crohn's Disease
Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease
The objectives of this study are to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06651600 (200 mg for 8 weeks followed by 50 mg for 4 weeks) dosed once daily and PF-06700841 (60 mg for…
- Trial name
- NCT03395184
- Testing
- PF-06651600, PF-06700841
- Where
- 195 sites in United States, Australia and 24 more
- Volunteers
- 244 people
- Sponsor
- Pfizer
Crohn's Disease
Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease
The primary objectives of the study are: To evaluate the safety and tolerability of MT-1303 in subjects with moderate to severe active Crohn's Disease（CD） To evaluate the clinical efficacy of MT-1303 in subjects with moderate to…
- Trial name
- NCT02378688
- Testing
- MT-1303
- Where
- 11 sites in Czechia, France and 9 more
- Volunteers
- 78 people
- Sponsor
- Tanabe Pharma Corporation
Severe Sepsis
Effect of a Sepsis Prediction Algorithm on Clinical Outcomes
In this clinical outcomes analysis, the effect of a machine learning algorithm for severe sepsis prediction on in-hospital mortality, hospital length of stay, and 30-day readmission was evaluated.
- Trial name
- NCT03960203
- Testing
- InSight
- Volunteers
- 75,147 people, healthy volunteers welcome
- Sponsor
- Dascena
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.